Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity

Starting soon · Phase 2 · Has a placebo group

Conditions studied: Anthracycline-induced Cardiotoxicity, Lymphoma, Chemotherapy, Cardiotoxicity

In brief

This project aims to determine the benefits of the dual SGLT1/2 inhibition as prophylactic treatment to prevent anthracycline-related cardiotoxicity.

Key facts

Study ID

NCT07572175

Run by

Icahn School of Medicine at Mount Sinai

People needed

60

Starts

2026-07-01

Expected to finish

2029-10-01

Last updated by the study team

2026-05-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients ≥ 18 years
• Newly diagnosed lymphoma
• Scheduled to receive high-dose anthracycline (cumulative dose ≥ 300 mg/m2)
• Eastern Cooperative Oncology Group (ECOG) performance status 0-3

You may not qualify if…

• Prior anthracycline treatment
• Previous malignancy requiring any chemotherapy or radiotherapy
• Previous treatment with SGLT2i (eg due to T2DM) or SGLT1/2i
• Previous heart failure (HF patients should already be on SGLT2i as per guidelines)
• LVEF<40% (even in the absence of HF):
• Pregnancy or breastfeeding
• Standard contraindication to MRI (claustrophobia, non-MRI compatible devices)

Where it is running

• Icahn School of Medicine at Mount Sinai — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.